Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
25
10
2023
medline:
11
12
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
ppublish
Résumé
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) exhibit glucose-lowering, weight-reducing, and blood pressure-lowering effects. Nevertheless, a debate exists concerning the association between GLP-1RA treatment and the risk of diabetic retinopathy (DR) in patients diagnosed with type 2 diabetes mellitus (T2DM). To ascertain the risk of DR in patients with T2DM undergoing GLP-1RA treatment, we conducted a meta-analysis utilizing data derived from randomized placebo-controlled studies (RCTs). A comprehensive literature search was conducted using PubMed, Cochrane Library, Web of Science, and EMBASE. We focused on RCTs involving the use of GLP-1RAs in patients with T2DM. Utilizing R software, we compared the risk of DR among T2DM patients undergoing GLP-1RA treatment. The Cochrane risk of bias method was employed to assess the research quality. The meta-analysis incorporated data from 20 RCTs, encompassing a total of 24,832 T2DM patients. Across all included trials, randomization to GLP-1 RA treatment did not demonstrate an increased risk of DR (odds ratio = 1.17; 95% CI 0.98-1.39). Furthermore, no significant heterogeneity or publication bias was detected in the analysis. The results of this systematic review and meta-analysis indicate that the administration of GLP-1 RA is not associated with an increased risk of DR. PROSPERO REGISTRATION IDENTIFIER: CRD42023413199.
Sections du résumé
BACKGROUND
BACKGROUND
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) exhibit glucose-lowering, weight-reducing, and blood pressure-lowering effects. Nevertheless, a debate exists concerning the association between GLP-1RA treatment and the risk of diabetic retinopathy (DR) in patients diagnosed with type 2 diabetes mellitus (T2DM).
OBJECTIVE
OBJECTIVE
To ascertain the risk of DR in patients with T2DM undergoing GLP-1RA treatment, we conducted a meta-analysis utilizing data derived from randomized placebo-controlled studies (RCTs).
METHODS
METHODS
A comprehensive literature search was conducted using PubMed, Cochrane Library, Web of Science, and EMBASE. We focused on RCTs involving the use of GLP-1RAs in patients with T2DM. Utilizing R software, we compared the risk of DR among T2DM patients undergoing GLP-1RA treatment. The Cochrane risk of bias method was employed to assess the research quality.
RESULTS
RESULTS
The meta-analysis incorporated data from 20 RCTs, encompassing a total of 24,832 T2DM patients. Across all included trials, randomization to GLP-1 RA treatment did not demonstrate an increased risk of DR (odds ratio = 1.17; 95% CI 0.98-1.39). Furthermore, no significant heterogeneity or publication bias was detected in the analysis.
CONCLUSION
CONCLUSIONS
The results of this systematic review and meta-analysis indicate that the administration of GLP-1 RA is not associated with an increased risk of DR. PROSPERO REGISTRATION IDENTIFIER: CRD42023413199.
Identifiants
pubmed: 37938535
doi: 10.1007/s40261-023-01319-x
pii: 10.1007/s40261-023-01319-x
doi:
Substances chimiques
Hypoglycemic Agents
0
Glucagon-Like Peptide-1 Receptor Agonists
0
Glucagon-Like Peptide 1
89750-14-1
Glucagon-Like Peptide-1 Receptor
0
Types de publication
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
915-926Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580–91. https://doi.org/10.1016/j.ophtha.2021.04.027 .
doi: 10.1016/j.ophtha.2021.04.027
pubmed: 33940045
Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156–86. https://doi.org/10.1016/j.preteyeres.2015.08.001 .
doi: 10.1016/j.preteyeres.2015.08.001
pubmed: 26297071
Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19061816 .
doi: 10.3390/ijms19061816
pubmed: 30597963
pmcid: 6337580
Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37: 101799. https://doi.org/10.1016/j.redox.2020.101799 .
doi: 10.1016/j.redox.2020.101799
pubmed: 33248932
pmcid: 7767789
Scanlon PH, Aldington SJ, Stratton IM. Epidemiological issues in diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20(4):293–300. https://doi.org/10.4103/0974-9233.120007 .
doi: 10.4103/0974-9233.120007
pubmed: 24339678
pmcid: 3841946
Simó R, Hernández C. What else can we do to prevent diabetic retinopathy? Diabetologia. 2023;66(9):1614–21. https://doi.org/10.1007/s00125-023-05940-5 .
doi: 10.1007/s00125-023-05940-5
pubmed: 37277664
pmcid: 10390367
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–56. https://doi.org/10.1016/j.cmet.2018.03.001 .
doi: 10.1016/j.cmet.2018.03.001
pubmed: 29617641
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–99. https://doi.org/10.1001/jama.2015.9676 .
doi: 10.1001/jama.2015.9676
pubmed: 26284720
Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26–37. https://doi.org/10.1016/j.diabres.2015.07.015 .
doi: 10.1016/j.diabres.2015.07.015
pubmed: 26358202
Simó R, Simó-Servat O, Bogdanov P, Hernández C. Neurovascular unit: a new target for treating early stages of diabetic retinopathy. Pharmaceutics. 2021. https://doi.org/10.3390/pharmaceutics13081320 .
doi: 10.3390/pharmaceutics13081320
pubmed: 34452281
pmcid: 8399715
Zheng D, Li N, Hou R, Zhang X, Wu L, Sundquist J, et al. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Med. 2023;21(1):40. https://doi.org/10.1186/s12916-023-02753-6 .
doi: 10.1186/s12916-023-02753-6
pubmed: 36737746
pmcid: 9898966
Vilsbøll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simó R, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889–97. https://doi.org/10.1111/dom.13172 .
doi: 10.1111/dom.13172
pubmed: 29178519
pmcid: 5888154
Yoshida Y, Joshi P, Barri S, Wang J, Corder AL, O’Connell SS, et al. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes—a systematic review and meta-analysis. J Diabetes Complicat. 2022;36(8): 108255. https://doi.org/10.1016/j.jdiacomp.2022.108255 .
doi: 10.1016/j.jdiacomp.2022.108255
Ueda P, Pasternak B, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, et al. Glucagon-like peptide 1 receptor agonists and risk of diabetic retinopathy complications: cohort study in nationwide registers from two countries. Diabetes Care. 2019;42(6):e92–4. https://doi.org/10.2337/dc18-2532 .
doi: 10.2337/dc18-2532
pubmed: 31010872
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160. https://doi.org/10.1136/bmj.n160 .
doi: 10.1136/bmj.n160
pubmed: 33781993
pmcid: 8005925
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928. https://doi.org/10.1136/bmj.d5928 .
doi: 10.1136/bmj.d5928
pubmed: 22008217
pmcid: 3196245
Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50. https://doi.org/10.1016/s0140-6736(19)31271-1 .
doi: 10.1016/s0140-6736(19)31271-1
pubmed: 31186120
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–55. https://doi.org/10.1007/s00125-009-1472-y .
doi: 10.1007/s00125-009-1472-y
pubmed: 19688338
pmcid: 2744824
Seino Y, Rasmussen MF, Nishida T, Kaku K. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52-week, randomized, multicenter trial. J Diabetes Investig. 2011;2(4):280–6. https://doi.org/10.1111/j.2040-1124.2011.00103.x .
doi: 10.1111/j.2040-1124.2011.00103.x
pubmed: 24843499
pmcid: 4014968
Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013;15(11):1000–7. https://doi.org/10.1111/dom.12121 .
doi: 10.1111/dom.12121
pubmed: 23627775
Ahrén B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141–8. https://doi.org/10.2337/dc14-0024 .
doi: 10.2337/dc14-0024
pubmed: 24898304
Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014;16(12):1257–64. https://doi.org/10.1111/dom.12382 .
doi: 10.1111/dom.12382
pubmed: 25155146
Home PD, Shamanna P, Stewart M, Yang F, Miller M, Perry C, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab. 2015;17(2):179–87. https://doi.org/10.1111/dom.12414 .
doi: 10.1111/dom.12414
pubmed: 25406730
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. https://doi.org/10.1056/NEJMoa1607141 .
doi: 10.1056/NEJMoa1607141
pubmed: 27633186
Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, Nishijima K, et al. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial. J Diabetes Investig. 2016;7(4):565–73. https://doi.org/10.1111/jdi.12457 .
doi: 10.1111/jdi.12457
pubmed: 27182042
pmcid: 4931207
Nauck MA, Stewart MW, Perkins C, Jones-Leone A, Yang F, Perry C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2016;59(2):266–74. https://doi.org/10.1007/s00125-015-3795-1 .
doi: 10.1007/s00125-015-3795-1
pubmed: 26577795
Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–301. https://doi.org/10.1210/jc.2018-00070 .
doi: 10.1210/jc.2018-00070
pubmed: 29688502
pmcid: 5991220
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29. https://doi.org/10.1016/s0140-6736(18)32261-x .
doi: 10.1016/s0140-6736(18)32261-x
pubmed: 30291013
Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–67. https://doi.org/10.1016/s2213-8587(19)30066-x .
doi: 10.1016/s2213-8587(19)30066-x
pubmed: 30833170
Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–32. https://doi.org/10.2337/dc19-0749 .
doi: 10.2337/dc19-0749
pubmed: 31186300
Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515–27. https://doi.org/10.1016/s2213-8587(19)30192-5 .
doi: 10.1016/s2213-8587(19)30192-5
pubmed: 31189517
Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262–71. https://doi.org/10.2337/dc19-0898 .
doi: 10.2337/dc19-0898
pubmed: 31530667
pmcid: 7364672
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51. https://doi.org/10.1056/NEJMoa1901118 .
doi: 10.1056/NEJMoa1901118
pubmed: 31185157
Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020;8(5):377–91. https://doi.org/10.1016/s2213-8587(20)30075-9 .
doi: 10.1016/s2213-8587(20)30075-9
pubmed: 32333875
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–84. https://doi.org/10.1016/s0140-6736(21)00213-0 .
doi: 10.1016/s0140-6736(21)00213-0
pubmed: 33667417
Frias JP, Choi J, Rosenstock J, Popescu L, Niemoeller E, Muehlen-Bartmer I, et al. Efficacy and safety of once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial. Diabetes Care. 2022;45(7):1592–600. https://doi.org/10.2337/dc21-2656 .
doi: 10.2337/dc21-2656
pubmed: 35671039
pmcid: 9274225
Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810–7. https://doi.org/10.1210/jc.2008-1518 .
doi: 10.1210/jc.2008-1518
pubmed: 18812476
Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009;11(5):498–505. https://doi.org/10.1111/j.1463-1326.2008.00992.x .
doi: 10.1111/j.1463-1326.2008.00992.x
pubmed: 19187286
Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117–28. https://doi.org/10.1056/NEJMoa1916038 .
doi: 10.1056/NEJMoa1916038
pubmed: 32233338
O’Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637–49. https://doi.org/10.1016/s0140-6736(18)31773-2 .
doi: 10.1016/s0140-6736(18)31773-2
pubmed: 30122305
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–409. https://doi.org/10.1016/s0140-6736(17)30069-7 .
doi: 10.1016/s0140-6736(17)30069-7
pubmed: 28237263
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57. https://doi.org/10.1056/NEJMoa1509225 .
doi: 10.1056/NEJMoa1509225
pubmed: 26630143
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827 .
doi: 10.1056/NEJMoa1603827
pubmed: 27295427
pmcid: 4985288
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–48. https://doi.org/10.1056/NEJMoa1616011 .
doi: 10.1056/NEJMoa1616011
pubmed: 28854085
Muskiet MHA, Tonneijck L, Smits MM, van Baar MJB, Kramer MHH, Hoorn EJ, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605–28. https://doi.org/10.1038/nrneph.2017.123 .
doi: 10.1038/nrneph.2017.123
pubmed: 28869249
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. https://doi.org/10.1016/s0140-6736(15)00803-x .
doi: 10.1016/s0140-6736(15)00803-x
pubmed: 26608256
9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125-s43. https://doi.org/10.2337/dc22-S009
Brooks AM, Lissett CA. A dramatic deterioration in diabetic retinopathy with improvement in glycated haemoglobin (HbA(1c)) on exenatide treatment. Diabet Med. 2009;26(2):190. https://doi.org/10.1111/j.1464-5491.2008.02650.x .
doi: 10.1111/j.1464-5491.2008.02650.x
pubmed: 19236627
Varadhan L, Humphreys T, Hariman C, Walker AB, Varughese GI. GLP-1 agonist treatment: implications for diabetic retinopathy screening. Diabetes Res Clin Pract. 2011;94(3):e68-71. https://doi.org/10.1016/j.diabres.2011.08.017 .
doi: 10.1016/j.diabres.2011.08.017
pubmed: 21906831
Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy. Diabetes Res Clin Pract. 2014;103(3):e37–9. https://doi.org/10.1016/j.diabres.2013.12.041 .
doi: 10.1016/j.diabres.2013.12.041
pubmed: 24456992
Simó R, Franch-Nadal J, Vlacho B, Real J, Amado E, Flores J, et al. Rapid reduction of HbA1c and early worsening of diabetic retinopathy: a real-world population-based study in subjects with type 2 diabetes. Diabetes Care. 2023;46(9):1633–9. https://doi.org/10.2337/dc22-2521 .
doi: 10.2337/dc22-2521
pubmed: 37428631
Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA(1c) change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care. 2021;44(1):290–6. https://doi.org/10.2337/dc20-1815 .
doi: 10.2337/dc20-1815
pubmed: 33444163
Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(10):933–41. https://doi.org/10.1007/s00592-017-1031-9 .
doi: 10.1007/s00592-017-1031-9
pubmed: 28748377
Douros A, Filion KB, Yin H, Yu OH, Etminan M, Udell JA, et al. Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy. Diabetes Care. 2018;41(11):2330–8. https://doi.org/10.2337/dc17-2280 .
doi: 10.2337/dc17-2280
pubmed: 30150234
Abcouwer SF, Gardner TW. Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann N Y Acad Sci. 2014;1311:174–90. https://doi.org/10.1111/nyas.12412 .
doi: 10.1111/nyas.12412
pubmed: 24673341
pmcid: 4154702
Hernández C, Bogdanov P, Corraliza L, García-Ramírez M, Solà-Adell C, Arranz JA, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes. 2016;65(1):172–87. https://doi.org/10.2337/db15-0443 .
doi: 10.2337/db15-0443
pubmed: 26384381
Simó R, Hernández C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes. 2017;66(6):1453–60. https://doi.org/10.2337/db16-1364 .
doi: 10.2337/db16-1364
pubmed: 28533296
Tang H, Li G, Zhao Y, Wang F, Gower EW, Shi L, et al. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis. Diabetes Obes Metab. 2018;20(5):1262–79. https://doi.org/10.1111/dom.13232 .
doi: 10.1111/dom.13232
pubmed: 29369494
Simó R, Bogdanov P, Ramos H, Huerta J, Simó-Servat O, Hernández C. Effects of the topical administration of semaglutide on retinal neuroinflammation and vascular leakage in experimental diabetes. Biomedicines. 2021. https://doi.org/10.3390/biomedicines9080926 .
doi: 10.3390/biomedicines9080926
pubmed: 34944588
pmcid: 8698405